MetaCap

Insight Molecular Diagnostics (IMDX) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed Insight Molecular Diagnostics (IMDX) over the past year, gaining 77.4% versus a loss of 67.4%. Over five years, TKNO leads with a -63.6% price change compared with -95.9% for IMDX. Alpha Teknova is the larger company by market cap ($480.0 million vs $80.9 million), about 5.9 times the size, while Insight Molecular Diagnostics is growing revenue faster (+115.6% vs +7.4%).

Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -1238.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMDX-67.38%TKNO+77.44%
+127%+22%-83%
Nov 21, 20251 yearNov 20, 2026
IMDX-96.43%TKNO-69.50%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMDX versus TKNO key metrics
MetricIMDXTKNO
Share price$1.97$7.63
Market cap$80.88M$479.95M
1-day change+18.67%-2.30%
YTD return-73.73%+100.79%
1-year return-67.38%+77.44%
5-year return-95.91%-63.63%
EPS (TTM)$-1.27$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.05M$40.52M
Revenue growth (YoY)+115.58%+7.35%
Net income (latest FY)$-50.22M$-17.26M
Gross margin56.67%33.17%
Operating margin-1260.76%-41.90%
Net margin-1238.52%-42.59%
52-week high$7.51$9.48
52-week low$1.50$1.91
Distance from 52-week high-73.77%-19.51%
Analyst consensusbuynone
Avg. price target upside+318.78%+28.83%
Average volume261.88K437.31K
Shares outstanding41.05M62.90M
Employees55158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alpha Teknova is about 5.9 times larger than Insight Molecular Diagnostics by market value ($479.95M vs $80.88M).
  • TKNO has outperformed IMDX by 144.8 percentage points over the past year.
  • Alpha Teknova is more profitable, keeping -42.6 cents of every revenue dollar as net income versus -1238.5 cents for Insight Molecular Diagnostics.
  • Insight Molecular Diagnostics grew revenue faster in its latest fiscal year (+115.58% vs +7.35%).

About Insight Molecular Diagnostics

IMDX stock →

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

IMDX vs TKNO FAQ

Which is bigger, Insight Molecular Diagnostics or Alpha Teknova?

Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $80.88M for Insight Molecular Diagnostics (IMDX).

Which stock has performed better over the past year, IMDX or TKNO?

TKNO returned +77.44% over the past 12 months, compared with -67.38% for IMDX (price return, excluding dividends). Past performance does not predict future results.

Are Insight Molecular Diagnostics and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons